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The bovine immunodeficiency virus (BIV) transactivator (BTat) recruits the bovine cyclin T1 (B-cyclin T1) to the LTR to
facilitate the transcription of BIV. Here, we demonstrate that bovine hexamethylene bisacetamide (HMBA)-induced
protein 1 (BHEXIM1) inhibits BTat-mediated BIV LTR transcription. The results of in vivo and in vitro assays show direct
binding of BHEXIM1 to the B-cyclin T1. These results suggest that the repression arises from BHEXIM1-BTat competition
for B-cyclin T1, which allows BHEXIM1 to displace BTat from B-cyclin T1. Furthermore, we found that the C-terminal
region and the centrally located region of BHEXIM1 are required for BHEXIM1 to associate with B-cyclin T1. Knockdown
of BHEXIM1 enhances BIV replication. Taken together, our study provides the first clear evidence that BHEXIM1 is
involved in BIV replication through regulating BTat-mediated transactivation.Introduction
Bovine immunodeficiency virus (BIV) belongs to the
Lentivirus genus of the Retroviridae family. It was initially
isolated from the leucocytes of an 8-year old Louisiana
dairy cow, R-29, that had persistent lymphocytosis, lymph-
adenopathy, central nervous system lesions and wasting
[1]. BIV infection has been detected in many countries
around the world using serological or molecular assays
[2-7]. Although most of these reports show BIV infection
is asymptomatic, BIV seropositivity is variably associated
with weight loss, secondary diseases, and diminished milk
production [5,7,8].
The BIV genome, like human immunodeficiency virus
(HIV) and other lentiviruses, contains the structural
genes gag, pol, env, and several accessory genes, includ-
ing tat, rev, vif, vpw, vpy, and tmx [9,10]. One of the
most studied regulatory proteins is the Tat protein,
which enhances viral gene expression [11]. The Tat pro-
teins of different lentiviruses are divided into two groups
depending on whether they bind TAR (transactivation* Correspondence: juantan@nankai.edu.cn
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reproduction in any medium, provided the orresponse region) to elevate viral gene expression. The
first group includes Tat proteins from BIV, Jembrana dis-
ease virus (JDV), HIV-1 and HIV-2, simian immunodefi-
ciency virus (SIV), and equine infectious anemia virus
(EIAV) [11,12]. These Tat proteins bind to the TAR present
at the 50 end of viral RNA transcripts and recruit the cellu-
lar positive transcription elongation factor b (P-TEFb),
which consists of the cyclin-dependent kinase 9 (CDK9)
and cyclin T1, to the viral promoter. Transcription elong-
ation is enhanced through Tat-mediated recruitment and
interaction with cyclin T1 and then CDK9-mediated phos-
phorylation of the carboxyl-terminal domain (CTD) of
cellular RNA polymerase II (RNAP II) [13-19]. It is note-
worthy that Tat from BIV (BTat) is distinct from other vi-
ruses of the first group because the recruitment of cyclin
T1 does not contribute to TAR binding [12,20]. Tat pro-
teins in the second group are from maedi-visna virus
(MVV), caprine arthritis-encephalitis (CAEV) and feline
immunodeficiency virus (FIV). These Tat proteins weakly
transactivate their homologous LTR in a TAR-independent
manner [21].
The hexamethylene bisacetamide (HMBA)-inducible pro-
tein 1 (HEXIM1) is a component of the inactive P-TEFb
[22]. Upon binding to 7SK snRNA, HEXIM1 oligomers
undergo a conformational change and then bind to cyclin. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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HEXIM1 inhibits the activity of CDK9 [23-26]. Through
this mechanism, HEXIM1 suppresses HIV-1 Tat transacti-
vation [27]. However, it is unknown whether HEXIM1
also interferes with BIV Tat transactivation. In this study,
we show that bovine HEXIM1 (BHEXIM1) was associated
with bovine cyclin T1 (B-cyclin T1) and suppressed BTat-
mediated BIV LTR transcription activation. Our results
further show that the nuclear localization signal and the
C-terminal domain of BHEXIM1 were essential for bind-
ing to B-cyclin T1. Knockdown of BHEXIMI increased
BIV replication, which further demonstrates the inhibitory
effect of BHEXIM1 on BTat function.Materials and methods
Materials
Protein A beads were purchased from Sigma (St. Louis,
MO, USA). Anti-Flag M2 monoclonal antibody (MAb)
was obtained from Stratagene (Agilent Technologies,
Santa Clara, CA, USA). Anti-HA rabbit antibody, anti-
HA mouse antibody, anti-β-actin C4 mouse antibody,
horseradish peroxidase-conjugated anti-rabbit and anti-
mouse secondary antibodies were obtained from Santa
Cruz Biotechnology (Dallas, Texas, USA).Plasmids and proteins
pBIV-LTR-Luc and pHIV-LTR-Luc plasmids were
constructed by subcloning BIV LTR or HIV LTR into
a pGL3-basic luciferase reporter vector (Promega,
Madison, WI, USA) upstream of the luciferase gene.
The BIV LTR and HIV LTR were provided by Dr. Charles
Wood (University of Nebraska Lincoln). pCMV-HA-
BHEXIM1 and pCMV-HA-HHEXIM1 were generated
by inserting BHEXIM1 or HHEXIM1 cDNA into the
expression vector, pCMV-HA (Clontech, Mountain
View, CA, USA). BHEXIM1 deletion mutants were cre-
ated by PCR and cloned into pCMV-HA. The mamma-
lian expression plasmid, Myc-BTat, was provided by
Dr Matjaz Barboric (University of California). pcDNA3.1
(+)-HTat (1-86 aa) was constructed by inserting HTat
(1-86 aa) into the pcDNA3.1(+) vector (Invitrogen, CA,
USA). The pcDNA-B-cyclin T1 (aa residues 1-272 of
bovine cyclin T1) was a kind gift from Dr. Alan Frankel
(University of California) [28] and was subcloned into
the pCMV-Tag2B vector (Stratagene). The pGEX6p-1
(Amersham Bioscience, Pittsburgh, PA, USA) and pETH
(Novagen, Darmstadt, Germany) vectors were used to con-
struct bacterial expression plasmids for GST- and His-
fusion proteins. Escherichia coli BL21 (DE3) strain cells
were transformed with these constructs to express GST-B
-cyclin T1, His-BHEXIM1, and His-BTat proteins. The
proteins were purified with glutathione Sepharose 4B beads
(GE healthcare, Pittsburgh, PA, USA) or His SepharoseTM6 (GE healthcare) according to the respective manufac-
turer’s instructions.
Cells and viruses
293 T, HeLa, fetal bovine lung (FBL) cells were primary
cells isolated from fetal bovine lung by our laboratory;
canine thymus cell line (Cf2Th), which is a BIV permis-
sive cell line, was kindly provided by Prof. Jin-Ming Gao
(Peking Union Medical College); and BIV baby hamster
kidney indicator cells, BIVL, which harbor the BIV LTR-
luciferase reporter [29], were maintained in Dulbecco’s
Modified Eagle Medium (DMEM, Gibco, CA, USA)
supplemented with 10% fetal bovine serum (FBS) and
2 mmol/L glutamine, 50 U/mL penicillin and 50 μg/mL
streptomycin sulfate. All of the cells were cultured at
37°C in 5% CO2. The R29 strain of BIV was provided by
Dr. Charles Wood (University of Nebraska Lincoln).
Tissue culture infectious dose endpoint (TCID50) of BIV
as BIV titers was evaluated by BIVL cells. Confluent
BIVL cells on 96-well plates were infected with 25 μL of
10-fold serial dilutions of stock viruses with eight paral-
lel wells for each dilution. Then the cells were incubated
at 37°C in 5% CO2 for 48 h. Examination of luciferase
activity was performed and the TCID50 was calculated
with the Reed-Muench method [29].
RNA isolation and RT-PCR
Total RNA was isolated from FBL cells using Trizol Re-
agent (Gibco) according to the manufacturer’s instructions.
Fifteen micrograms of total RNA was used for cDNA syn-
thesis using Moloney murine leukemia virus (M-MLV) re-
verse transcriptase (RT) (Promega). BHEXIM1 sequences
were amplified by polymerase chain reaction (PCR) using
the following primers: forward, 50- GTGGAATTCAAAT
GGCCGAGCCACT-30; reverse, 50- AGCCTCGAGCTAG
TCTCCAAAGTTG-30.
Small hairpin RNA (shRNA) treatments
The pSIREN-RetroQ (Clontech) was used to construct
the shRNA-BHEXIM1 plasmid, which targets the
CAGCGATGAGGACTTTATG sequence. A control
shRNA targeting sequence GACAGAACCAGAGGA
TAGA, which does not pair with any eukaryotic mRNA,
was used. The lentiviral shRNA system was used in this
study as previously described [30]. Briefly, stock lentivi-
ruses were produced by transfecting 293 T cells. Super-
natants were harvested at 48 h post-transfection and
were then stored at -80°C. To generate the BHEXIM1
downregulated cells, FBL cells were infected with stock
lentiviruses for 12 h and then the virus was washed away.
At 48 h after infection, puromycin (2 μg/mL) was added to
the cultures to select for BHEXIM1-downregulated cells.
The amounts of BHEXIM1 and GAPDH mRNA in
shRNA-BHEXIM1 or shRNA-control treated FBL cells
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performed using the IQ5 Multicolor real-time PCR de-
tection system (Bio-Rad, Hercules, CA, USA) and SYBR
green real-time PCR master mix (Toyobo, Osaka, Japan)
according to the manufacturers’ instructions. The se-
quences of the primer pairs were as follows: BHEXIM1
forward (50-ACGACACCAGCGATGAGGAC-30) and re-
verse (50-TCCAGCCGCAGCCGATTATT-30); BIV capsid
protein-CA forward (50-AAGGAGCCGTACACAGACT
T-30) and reverse (50-TTCTGGAGCCGCCATACCTT-30);
and GAPDH, which was used as an internal control, for-
ward (50-AACGGCACAGTCAAGGCAGA-30) and reverse
(50-TCGGCAGAAGGTGCAGAGAT-30). The specificity
of the amplification reaction was verified by melting-curve
analyses. Threshold cycle (CT) values were calculated
automatically as the cycle when the sample fluores-
cence exceeded a threshold level corresponding to 10
standard deviations (SD) of the mean of the baseline
fluorescence. The level of BHEXIM1 and CA expres-
sion was normalized to GAPDH using the 2-ΔΔCT
method [31].
Luciferase assay
Cf2Th cells were plated in 12-well plates (1 × 105/well)
and cultured at 37°C for 20 h before transfection using
polyethylenimine (PEI; sigma). The total DNA in each
transfection mixture was normalized using empty vec-
tor DNA. pCMV-β-gal plasmid DNA (0.1 μg) was in-
cluded in each transfection. Cells were harvested at
48 h after transfection. The luciferase activity was mea-
sured using a commercial assay system (Promega). The
cells were rinsed with PBS and lysed with lysis buffer
(Promega). The cell lysates were then clarified from
the insoluble materials by centrifugation at 12 000 rpm
for 3 min. The clarified lysate (5 μL) was mixed with
the luciferin reagent (50 μL) and luciferase activity
was measured in a chemiluminescence measurement
machine (Promega). Simultaneously, 50 μL clarified
lysate was mixed with the same volume (50 μL) of
o-Nitrophenyl-β-D-Galactopyranoside (ONPG) buffer
(4.4 mM ONPG, 4.3 mM MgCl2-6H2O, 164 mM
Na2HPO4-12H2O, 36 mM NaH2PO4-2H2O, 0.684%
β-mercaptoethanol). The activity of β-galactosidase
was then examined at OD405 nm with a Precision
Microplate Reader (Molecular Devices, Sunnyvale,
CA, USA) until the results ranged between 0.200 and
0.800. The results were used as an internal control to
normalize the efficiency between transfections by the
formula: (each well of luciferase activity) / (each well
of β-galactosidase activity - the background of β-
galactosidase activity). The luciferase activity of each
well divided by the control well was expressed as the
relative luciferase activity (fold). Each experiment was
repeated at least three times.Western blotting
Cf2Th cells plated in 12-well plates (1 × 105/well) were
transfected with various plasmids. Fourty-eight hours
post-transfection, the cells were harvested and washed
twice with 1× phosphate buffered saline. The cells were
then lysed with NP-40 lysis buffer (0.5% NP-40, 0.1%
Triton X-100, 0.1% sodium deoxycholate, 10 mM Tris-
Cl, 150 mM NaCl, 1 mM EDTA) containing 1% PMSF
for 30 min on ice. After centrifugation at 10 000 × g for
10 min at 4°C, the supernatants were collected, and pro-
tein concentrations were measured using the Bio-Rad
Protein Assay reagent (Catalog No. #500-0006). The
samples (30 μg/lane) were separated by 12% polyacryl-
amide gel electrophoresis (SDS-PAGE). The proteins
were then transferred onto a polyvinylidene difluoride
(PVDF) membrane (Millipore, Billerica, MA, USA) by
electroblotting for 1 h at 100 V, 4°C. Following incuba-
tion in 5% nonfat milk (in 1× phosphate-buffered saline)
for 45 min at room temperature, the membrane was
blotted with primary antibody for 90 min at room
temperature and then incubated with goat anti-mouse
or goat anti-rabbit secondary antibodies conjugated with
peroxidase.
Co-immunoprecipitation (Co-IP) and Pulldown assays
For the co-immunoprecipitation assay, a total of 1 × 107
293 T cells in 100-mm-diameter dishes were transfected
with various plasmids using the PEI reagent. Cells were
harvested at 48 h after transfection; lysed in 600 μL lysis
buffer (50 mM Tris-HCl [pH8.0], 150 mM NaCl, 1%
NP-40, and 1 mM phenylmethylsulfonyl fluoride); soni-
cated; and centrifuged for 15 min at 4°C, 10 000 × g.
The supernatant was incubated with antibody at 4°C for
2 h. Thirty microliters of protein A beads was then
added, and the mixture was incubated for an additional
2 h at 4°C. Immunocomplexes were washed five times
with the lysis buffer and then boiled in SDS loading buf-
fer. The precipitated proteins were detected by SDS-
PAGE and immunoblotting. For the GST pulldown assay,
purified GST and GST-fusion proteins were immobilized
on glutathione Sepharose 4B beads, and then incubated
with purified His-fusion proteins. After extensive washing,
the beads were boiled in SDS loading buffer and the pro-
teins were subjected to SDS-PAGE and immunoblotting.
Results
BHEXIM1 inhibits LTR transcriptional activation by BTat
We first cloned the BHEXIM1 gene [GenBank:
NM_001076181] from FBL cells by RT-PCR. BHEXIM1
has 320 amino acids and is therefore 39 amino acids
shorter than its human counterpart. The amino acid resi-
dues 102, 103 and 107 to 143 in human HEXIM1 are
missing in BHEXIM1. The human and bovine HEXIM1
mainly differ in their N-terminal regions (Figure 1A). We
Figure 1 BHEXIM1 inhibits BTat transactivation of LTR transcription. (A) Sequence comparison of the bovine and human HEXIM1 proteins.
Amino acid differences between the two proteins are shown in shaded boxes. Amino acid deletion (•) is indicated. (B) HeLa cells were
transfected with 0.05 μg of the reporter plasmid pHIV LTR-Luc, 0.01 μg of the pCMV-β-gal plasmid, and combined with the indicated amount of
HA-HHEXIM1 and with or without HTat (0.025 μg) (left panel). Cf2Th cells were co-transfected with the BIV LTR-Luc plasmid (0.05 μg), the pCMV-β
-gal plasmid (0.1 μg), and the indicated amount of the HA-BHEXIM1 expression plasmid with or without BTat (0.025 μg) (right panel). After 48 h,
the relative luciferase activities were analyzed. The relative expression of HA-HHEXIM1 or HA-BHEXIM1 in the transfected cells was monitored by
WB assay (bottom panel). Error bars represent the SD of the means from three independent experiments.
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transactivation. HeLa cells were transfected with a lu-
ciferase reporter plasmid under the control of the HIV
LTR, along with increasing amounts of HHEXIM1
with or without HTat. The results show that HHEXIM1
reduced HTat-mediated HIV LTR transactivation in a
dose-dependent manner (Figure 1B, left panel). We next
asked whether BHEXIM1 modulates the function of
BTat in transactivating the BIV LTR. To answer this
question, the BIV-LTR-Luc reporter construct was
used to monitor the transcriptional activity of the BIV
LTR promoter. A BIV permissive cell line, Cf2Th, was
transfected with pLTR-Luc reporter plasmid and in-
creasing amounts of BHEXIM1 in the absence or pres-
ence of BTat. As shown in Figure 1B (right panel),
BHEXIM1 inhibited BTat-induced transactivation in a
dose-dependent manner. Therefore, the results suggestedthat BHEXIM1 diminishes the transactivation of the BIV
LTR by BTat.
BHEXIM1 interacts directly with B-cyclin T1
To determine whether BHEXIM1 associated with P-TEFb,
we first tested the interaction between BHEXIM1 and
B-cyclin T1. 293 T cells were co-transfected with HA-
BHEXIM1 and Flag-B-cyclin T1 constructs. Following
immunoprecipitation with HA antibodies, the precipitates
were examined by western blot with anti-Flag antibodies.
The results show that Flag-B-CyclinT1 was co-immucx
cnoprecipitated with HA-BHEXIM1 (Figure 2A). Simi-
larly, HA-BHEXIM1 was co-immunoprecipitated with
Flag-B-cyclin T1 (Figure 2B). To determine whether
BHEXIM1 interacted directly with B-cyclin T1 in vitro,
His-BHEXIM1 and GST-B-cyclin T1 were expressed in
E.coli and purified using the protein expression system.
Figure 2 BHEXIM1 interacts directly with B-cyclin T1. (A) Co-IP of BHEXIM1 and B-cyclin T1. 293 T cells were co-transfected with Flag-B-cyclin
T1 and either an empty vector (lane 1) or HA-BHEXIM1 (lane 2). BHEXIM1 was immunoprecipitated with rabbit anti-HA agarose beads, and the
immunoprecipitates were detected by western blot using mouse anti-Flag (top) or mouse anti-HA (middle) antibodies. The amount of B-cyclin T1
in each cell lysate was checked using a mouse anti-Flag antibody (bottom). (B) Reciprocal Co-IP of BHEXIM1 and B-cyclin T1. 293 T cells were co-
transfected with HA-BHEXIM1 and either an empty vector (lane 1) or Flag-B-cyclin T1 (lane 2). B-cyclin T1 was immunoprecipitated with mouse
anti-Flag agarose beads, and the immunoprecipitates were detected by western blot using rabbit anti-HA (top) or mouse anti-Flag (middle)
antibodies. The amount of BHEXIM1 in the cell lysates was checked using a rabbit anti-HA antibody (bottom). (C) In vitro interaction between
BHEXIM1 and B-cyclin T1. The purified BHEXIM1 protein was incubated with GST or GST-B-cyclin T1 agarose beads. GST pulldown was then
performed, and precipitates were detected by western blot using an anti-His antibody. Purified His-BHEXIM1, GST and GST-B-cyclin T1 used in the
pulldown assay were detected by Coomassie blue staining.
Figure 3 BHEXIM1 competes with BTat for binding B-cyclin T1.
GST (lane 1, 20 μg) or GST-B-cyclin T1 (lane 2-6, 20 μg) was
incubated with His-BTat (5 μg). Increasing amounts of His-BHEXIM1
(1, 5, 10, 20 μg) were added to the reactions in lane 3-6 but not lane
1 and 2. GST pulldown was then performed, and the purified GST
and GST-B-cyclin T1 used in the pulldown assay were detected by
Coomassie blue staining (top). The bound BTat and BHEXIM1 were
detected using an anti-His antibody (middle). The amount of BTat
and BHEXIM1 in the cell lysates were checked using an anti-His
antibody (bottom).
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BHEXIM1 was eluted with GST-B-cyclin T1, suggesting
a direct association between BHEXIM1 and B-cyclin
T1 (Figure 2C). Taken together, these results demon-
strate a direct interaction between BHEXIM1 and B-
cyclin T1.
BHEXIM1 interferes with the interaction of BTat and B-
cyclinT1
Previous studies demonstrated that Tat stimulates the syn-
thesis of viral mRNA via the interaction with cyclin T1
[32] and showed that HHEXIM1 and HIV-1 Tat binds
cyclin T1 in a mutually exclusive fashion [33,34]. To test
whether BHEXIM1 competed with BTat for binding to B-
cyclin T1, we used purified recombinant proteins to study
the interactions of BHEXIM1 and BTat with GST-B-cyclin
T1 (aa 1-272). The data in Figure 3 show that BTat bound
to GST-B-cyclin T1 but not GST alone in the absence of
BHEXIM1 (compare lanes 1 and 2). However, BHEXIM1
protein reduced the amount of BTat bound to GST-B
-cyclin T1 (compare lanes 4-6 to 2). When the ratio of
BHEXIM1 and BTat reached 4:1 (lane 6), BTat was com-
pletely displaced from GST-B-cyclin T1 by BHEXIM1.
These results suggest that BHEXIM1 competes with BTat
in binding to B-cyclin T1.
Identification of protein sequences involved in BHEXIM1
binding to B-cyclin T1 and inhibiting the transactivation
function of BTat
We next investigated which regions of BHEXIM1 are re-
quired for binding to B-cyclin T1. To this end, we gener-
ated three BHEXIMI mutants named 104-320, 1-140 and
Δ(108-140) that lack the amino acids 1-104, 140-320 and
108-140 respectively (Figure 4A). 293 T cells were then
transfected with plasmids expressing either the wild-typeor truncated BHEXIM1 tagged with HA, together with
the Flag-B-cyclin T1 plasmid. A co-immunoprecipitation
assay shows that 1-320 aa (full-length) and 104-320 mu-
tant were able to interact with Flag-B-cyclin T1, but the
1-140 and Δ(108-140) mutant lost the interaction
(Figure 4B). Therefore, the central region between re-
sidues 108 and 140 and the C-terminal domain of
BHEXIM1 were essential for binding to B-cyclin T1.
Cf2Th cells were also transfected with the LTR-Luc re-
porter plasmid and different truncations of BHEXIM1,
with or without BTat. The results show that the removal
Figure 4 Identification of the BHEXIM1 domain responsible for
binding to B-cyclin T1 and inhibiting BTat transactivation.
(A) Schematic representation of HA-tagged truncation forms of
BHEXIM1. (B) 293 T cells were co-transfected with an empty vector,
BHEXIM1, or the indicated truncations together with Flag-B-cyclin T1.
BHEXIM1 was immunoprecipitated with rabbit anti-HA agarose
beads, and the immunoprecipitates were detected by western blot
using a mouse anti-Flag (top) or mouse anti-HA (middle) antibody.
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did not eliminate the inhibition. However removal of
the C-terminal amino acids (1-140) and the central re-
gion significantly affected the inhibition (Figure 4C).
Thus, BHEXIM1-mediated repression required the
presence of the C-terminal domain and the central re-
gion between residues 108 and 140.The amount of B-cyclin T1 in the cell lysates was checked using an
anti-Flag antibody (bottom). (C) Cf2Th cells were co-transfected with
a BIV LTR-Luc plasmid (0.05 μg), pCMV-β-gal plasmid (0.1 μg),
wild-type BHEXIM1 or the deletion form of BHEXIM1 (0.1 μg) with or
without BTat (0.025 μg), and an empty vector to ensure that the
total DNA concentration in each transfection mixture was constant.
After 48 h, the relative luciferase activities were analyzed. All of the
luciferase activities with Tat were divided by the luciferase activities
without Tat. Error bars represent the SD of the means from three
independent experiments.Knockdown of BHEXIM1 enhances BIV replication
We next measured the effect of knockdown of endogen-
ous BHEXIMI on BIV infection. First, we transduced the
FBL cells with shRNA targeting BHEXIMI and gener-
ated a stable knockdown cell line with an 80% decrease
of BHEXIM1 mRNA (Figure 5A). We then used BIV to
infect the BHEXIM1 knockdown cells and control cells.
Twenty-four hours after infection, the levels of viral
RNA were measured by RT-PCR. As shown in Figure 5B,
the viral RNA level was increased by approximately
2-fold in BHEXIM1 stable-knockdown cells compared to
control cells. To determine the amounts of infectious BIV
produced, the infected BHEXIM1 knockdown FBL cells or
control cells were co-cultured with the BIV indicator cell
line, BIVL, and the luciferase activity was measured 48 h
later. The results show an approximately two-fold in-
crease in luciferase activity (Figure 5C). Taken together,
the data suggest that BIV replication was enhanced
when BHEXIM1 was down-regulated in infected cells.
Discussion
Viruses are obligate intracellular parasites and must em-
ploy cellular machinery for their efficient replication.
Meanwhile, host cells evolve different strategies to sup-
press or eliminate viral infection and replication. BTat is
an early regulatory protein, and it plays an essential role
in the BIV life cycle. Transcriptional transactivation of
the BIV LTR by essential BTat requires recruitment of
cyclin T1 to the BIV TAR to enhance viral transcription
elongation. HEXIM1 as a host cellular P-TEFb inhibitor
may regulate Tat function and viral replication.
Our study was the first one to report the role of bovine
HEXIM1 in BTat transactivation and BIV replication. Our
data demonstrate that BHEXIM1 inhibited BTat-mediated
BIV LTR transactivation by direct interaction with B-cyclin
T1. The results of the competition assay further show that
BHEXIM1 disrupted BTat binding to B-cyclin T1. Finally,
Figure 5 RNAi Knockdown of BHEXIM1 in FBL cells enhances BIV replication. (A) FBL cells were stably transfected with either BHEXIM1-
specific (shBHEXIM1) or control (shCON) shRNA oligonuceotides. Cellular RNA was extracted and subjected to real-time PCR to examine the
amount of BHEXIM1 and GAPDH. (B) BHEXIM1-knockdown (shBHEXIM1) and control (shCON) FBL cells (5 × 105/well) were infected with 5 × 103
TCID50 BIV. The mRNA level of BIV CA was examined by real-time PCR at 24 h post-infection. (C) BHEXIM1-knockdown (shBHEXIM1) and control
(shCON) FBL cells (5 × 104/well) were infected with 5 × 102 TCID50 BIV. At 24 h post-infection, BIVL (1 × 10
5/well) was added and the luciferase
activity was assayed after 48 h co-culture. Error bars represent the SD of the means from three independent experiments.
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and production of BIV, indicating the regulatory role of
BHEXIMI involved in BIV infection.
BHEXIM1 and HHEXIM1 share 80.50% homology in
their amino acid sequences and both proteins have three
main domains. Comparing to other parts of the two pro-
teins, the N-terminal domain (NTD) exhibited a lower
homology (57.05%), which is reported to be the self-
inhibitory domain [35], because a 39 amino acid deletion
was found in BHEXIM1. The central region contains an
arginine-rich motif (ARM) and functions as the nuclear
localization signal (NLS). This region serves as the 7SK-
binding site [26,36] and shows 92.86% homology between
HHEXIM1 and BHEXIM1. Only two amino acids differ
in the central regions of BHEXIM1 and HHEXIM1. The
C-terminal domain is rich in acidic residues and shows
96.17% homology between HHEXIM1 and BHEXIM1.
This region contains the coiled-coil domain and the con-
served PYNT motif. In HHEXIM1, this region mediates
direct interaction with P-TEFb [26]. The high homology
between BHEXIM1 and HHEXIM1, especially in their
central and C-terminal regions, indicates their conserved
structures and functions.
A recent report suggested that HTat competes with
HHEXIM1 for binding to cyclin T1 [33], displaying the re-
ciprocal competition between HHEXIM1 and cyclin T1.
The apparent discrepancy may be explained by the fact
that higher amounts of BHEXIM1 compared to BTat
exhibited the advantage of binding B-cyclin T1 and could
displace BTat from B-cyclin T1. The central region of
BHEXIM1, which may be involved in nucleus localization
and 7SK RNA binding, was also proved to be important in
BHEXIM1 binding B-cyclin T1 and inhibiting the transac-
tivation function of BTat, consistent with previously dem-
onstrated roles of HHEXIM1 on HIV [26,36]. When the
native HEXIM1 NLS was replaced with a foreign NLS se-
quence, the NLS-substituted HEXIM1 mutants failed tointeract with P-TEFb. Thus, the arginine-rich 7SK-binding
motif within the NLS of HEXIM1 was indispensable for
HEXIM1’s inhibitory effect on transcription through
7SK as a molecular scaffold-mediated interaction with
P-TEFb. The essential role of this domain indicated the
crucial function of 7SK RNA in the interaction between
BHEXIM1 and B-cyclin T1 and the potential role of
BHEXIM1/7SK RNA interaction in BTat inhibition.
Future studies on the function of 7SK RNA in BIV
transactivation may be necessary to evaluate the pro-
posed hypothesis.
In summary, this study demonstrates the repression of
BHEXIM1 on BTat transactivation by competing with
BTat for binding to B-cyclin T1, allowing it to directly
displace BTat from B-cyclin T1. Furthermore, we found
that the C-terminal region and the centrally located 7SK
snRNA recognition region of BHEXIM1 are essential for
repression. Knockdown of BHEXIM1 enhances BIV rep-
lication. Based on the data presented in this study, we
propose the potential impact of BHEXIM1 on the BIV
latent life cycle and the absent clinical disease signs of
infected livestock. This finding may provide important
information for BIV molecular biology and clinical diag-
noses and prevention.
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